TNDM
Tandem Diabetes Care Inc is a provider of medical care devices in the United States. Its products aid in the delivery of insulin and getting accurate readings through its software application.
Tandem Diabetes Care, Inc. (TNDM) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Value (D+). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | D+ (1.5) | B- (3.1) | B- (2.9) | B- (3.0) | C+ (2.6) | C+ (2.6) |
| 2026-11-08 | C- (1.9) | B (3.2) | B- (2.9) | C (2.4) | C+ (2.6) | C+ (2.6) |
| 2026-11-01 | D+ (1.6) | B- (3.1) | C+ (2.8) | C+ (2.5) | C+ (2.7) | C+ (2.5) |
| 2026-10-25 | D+ (1.8) | B- (3.1) | C+ (2.8) | C (2.3) | C+ (2.6) | C+ (2.5) |
| 2026-10-18 | C- (1.9) | B- (3.1) | C+ (2.8) | C (2.4) | C+ (2.6) | C+ (2.6) |